Figure 1
Kahraman’s visual assessment in 123I-FP-CIT SPECT images. (A) Grade 1 (normal), (B) Grade 2 (eagle wing), (C) Grade 3 (mixed), (D) Grade 4 (egg shape), and (E) Grade 5 (burst striatum).
Table 1
Patients characteristics.
| With LID (n = 4) | Without LID (n = 21) | P value | |
|---|---|---|---|
| Age (years) | 59.3 ± 2.14 | 63 ± 1.89 | 0.411 |
| Sex (M/F), n | 0/4 | 11/10 | 0.09a |
| Disease duration (months) | 106.8 ± 24.8 | 48.8 ± 6.98 | <0.001 |
| Age at onset (months) | 50.3 ± 3 | 59.8 ± 1.98 | 0.057 |
| Duration of LID (months) | 66.7 ± 15.9 | ||
| MSA-C/MSA-P | 1/3 | 9/12 | 0.627 |
| Levodopa responsiveness | 4/4 | 9/21 | <0.05 |
| Hoehn & Yahr stage | 4.5 ± 0.29 | 3.7 ± 0.14 | 0.130 |
| Rigidity on UPDRS part III | 5.75 ± 1.54 | 4.48 ± 0.96 | 0.587 |
| Akinesia on UPDRS part III | 15.3 ± 2.84 | 11.5 ± 1.27 | 0.222 |
| LDD (mg) | 600 ± 141 | 426 ± 98 | 0.449 |
| LDD/body weight (mg/kg) | 15.8 ± 3.6 | 7.8 ± 2.0 | 0.122 |
| LED (mg) | 1053 ± 158 | 494.6 ± 495 | 0.0424 |
| LED/Body weight (mg/kg) | 25.9 ± 8.7 | 9.95 ± 11 | 0.0162 |
| Specific binding ratio (average) | 0.64 ± 0.42 | 2.54 ± 0.36 | <0.05 |
[i] Abbreviations: LID: levodopa-induced dyskinesia, MSA-C: cerebellar-type multiple system atrophy, MSA-P: Parkinson-type multiple system atrophy, UPDRS: Unified Parkinson’s Disease Rating Scale, LDD: levodopa dose, LED: levodopa equivalent dose. p Value was obtained by t-test. p Valuea was obtained by fisher’s exact test (median (interquartile range)).
Figure 2
Correlation of dopamine transporter single-photon emission computed tomography visual assessment grade and disease duration. (A) disease duration, (B) bradykinesia (finger tapping, rapid alternating movement, and foot tapping), (C) rigidity (neck and limbs).
Open circle; MSA patients with dyskinesia, closed circle; MSA patients without dyskinesia. p Value was obtained by Pearson’s correlation coefficient.
Abbreviation: UPDRS: Unified Parkinson’s Disease Rating Scale.